An interventional study of Face to face and telephonic interviews in No Metastatic Breast Cancer, sponsored by Institut de Cancérologie de Lorraine. Active, not recruiting at 1 site in France. Open to female participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-09-01.
Sponsored by Institut de Cancérologie de Lorraine · Not applicable, Interventional, and Supportive care
EFACog is a single-center prospective cohort feasibility study conducted on a single group of patients to study the feasibility of a personalized support program by a nurse conducted over 9 months, using face-to-face and telephone interviews. The objective of this support program is to prevent the occurrence of post-chemotherapy cognitive impairment. After a pre-inclusion visit, patients with no pre-existing cognitive impairment will be included in the study and will receive a 9-month follow-up after the first course of chemotherapy. All follow-up visits (telephone or face-to-face) will be scheduled in conjunction with those taking place in the care setting.
Institut de Cancérologie de Lorraine is the lead sponsor of 62 studies on the registry; 5 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Other: Face to face and telephonic interviews
face to face interview : before the first chemotherapy treatment (M0), then at 3 months (M3), 6 months (M6) and 9 months (M9) after the first chemotherapy treatment. Telephonic interview : every month between two face-to-face interviews, i.e. at 1 month after the first treatment (M1), at 2 months (M2), at 4 months (M4), at 5 months (M5), at 7 months (M7) and at 8 months (M8) after the first chemotherapy treatment.
To assess program feasibility
Rate of patients who participated in all provider interviews (face-to-face and telephone contacts).
Time frame: 9 months
The cognitive complaint
The cognitive complaint will be assessed by the FACT-Cog questionnaire comprising 37 items.
Time frame: 9 months
The Quality of life of patients
Quality of life will be assessed by the generic QLQ-C30 questionnaire of 30 items.
Time frame: 9 months
Fatigue
Fatigue will be assessed by the QLQ-FA12 questionnaire of 12 items.
Time frame: 9 months
Anxiety and depression
Anxiety/depression will be assessed by the 14-item HADS questionnaire (7 items: anxiety / 7 items: depression).
Time frame: 9 months
Appearance of neurocognitive disorders and/or significant cognitive complaints
The appearance of neurocognitive disorders and/or significant cognitive complaints will be assessed by taking the MoCA (Montreal Cognitive Assessment) and QPC (Semi-structured Cognitive Complaint Questionnaire) tests.
Time frame: 9 months
Satisfaction of patients
Satisfaction will be assessed by a numerical scale (0: not satisfied to 10: very satisfied).
Time frame: 9 months
This study is active, not recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Institut de Cancérologie de Lorraine